Hosted on MSN1mon
Merck rival Summit draws new buy from Truist on deal prospectsSummit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback